NiveshIQNiveshIQ
NSE: NEPHROPLUS  ·  Healthcare

Nephrocare Health Services Ltd.

₹648.95▼ ₹10.80 (-1.64%)
Volume: 238,796Day Range: ₹636.85 – ₹662.0052W Range: ₹446.00 – ₹781.50
Price Chart  ·  Daily closes
1Y 6M 3M 1M 1W 1D
⚡ Intelligence Signals 5 active
🟢 Bullish Earnings Catalyst 📊 RS Laggard (5D) 🔄 Sector Sweep ⚡ Signals Aligned 📉 Pullback

NiveshIQ has detected 5 active signals on NEPHROPLUS. Sign up free to see what each signal means and how it affects the stock.

Unlock signals — free
Expected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74 / 100

About Nephrocare Health Services Ltd.

Nephrocare Health Services Limited operates a network of dialysis clinics and centers across India, Uzbekistan, Nepal, and the Philippines, offering in‑clinic, on‑call, home hemodialysis, holiday dialysis, and mobile dialysis services. The company’s core revenue drivers are the high volume of dialysis treatments and ancillary services such as laboratory testing and medication dispensing. In FY2023, Nephrocare reported revenue of ₹1,053 crore and a net income of ₹85 crore, reflecting a 12% YoY revenue growth and a 15% improvement in operating margin. Recent developments include the expansion of its home hemodialysis program, which has increased patient retention and reduced facility costs. Nephrocare’s competitive position is strengthened by its first‑mover advantage in the Indian dialysis

Financial Highlights

MetricFY26
Revenue₹994.47 Cr +32.90%
EBITDA Margin24.63%
Net Profit₹76.84 Cr +14.50%
EPS₹8.48

Annual figures in Indian Rupees (Crores). Source: BSE filings.

Analyst ConsensusConsensus target ₹847.50  |  Buy 4 · Hold 0 · Sell 0Sign in to see →

Strategic Outlook

Patient volumes, occupancy, ARPOB/ARPO, case mix, and bed-capacity ramp-up remain the key forward drivers for the next 2...

FY26 (last completed FY): revenue ₹994 Cr, PAT ₹77 Cr, EBITDA margin 24.6%, EPS ₹8.48. Year-on-year: revenue YoY +32.9%,...

🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instant

Everything you unlock with a free account

⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NEPHROPLUS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NEPHROPLUS alongside your other holdings
Unlock full NEPHROPLUS research — free
No credit card  ·  No trial  ·  Always free to start

Frequently Asked Questions

What AI signals does NiveshIQ provide for Nephrocare Health Services Ltd.?

NiveshIQ detects active intelligence signals for Nephrocare Health Services Ltd. (NEPHROPLUS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.

What are the key financials for Nephrocare Health Services Ltd.?

Nephrocare Health Services Ltd. operates in the Healthcare sector with a market capitalisation of ₹652,577.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.

Does NiveshIQ provide investment advice?

No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.

Viewing preview of Nephrocare Health Services Ltd. — 5 active signals detected Unlock full analysis — free